RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Consumer reactions to price comparison and disclosure information in prescription drug print advertising
Aikin, K. J., Betts, K. R., Southwell, B. G., Boudewyns, V., Johnson, M., & Stine, A. D. (2019). Consumer reactions to price comparison and disclosure information in prescription drug print advertising. Journal of Consumer Affairs, 53(3), 1255-1272. https://doi.org/10.1111/joca.12227
Advertisers sometimes include price-comparison information in direct-to-consumer (DTC) prescription drug ads because consumers may value such savings when considering drug options. It is not known whether a context statement—a disclosure noting that compared products may or may not be equally effective or safe or costly—could improve consumer understanding of risk, efficacy, and price. Using a between-subjects experiment, we tested effects of price claim type (price comparison versus general cost savings) and presence of a disclosure statement in a fictitious but professionally developed DTC prescription drug print ad. Results indicated that when people remembered seeing the disclosure, they demonstrated uncertainty regarding risks, efficacy, and savings; however, most did not notice the disclosure, despite its prominent placement in the ad.